March 2016 News Recap

Daratumumab would become the sole anti-CD38 agent available for all newly diagnosed multiple myeloma types if approved.

Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.

Data from the DESTINY-Breast06 trial support the positive opinion on trastuzumab deruxtecan as a treatment in HER2-low or HER2-ultralow breast cancer.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Antitumor efficacy end points favored placebo over trilaciclib prior to FOLFOXIRI/bevacizumab in patients with untreated metastatic colorectal cancer.

One of the most predictable toxicities of autologous stem cell transplantation for multiple myeloma — even more so than mucositis — is hair loss.